439 related articles for article (PubMed ID: 29245103)
1. Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.
Kelly MM; Reilly E; Quiñones T; Desai N; Rosenheck R
Drug Alcohol Depend; 2018 Feb; 183():111-117. PubMed ID: 29245103
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration.
Manhapra A; Quinones L; Rosenheck R
Drug Alcohol Depend; 2016 Mar; 160():82-9. PubMed ID: 26804898
[TBL] [Abstract][Full Text] [Related]
3. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors.
Oliva EM; Harris AH; Trafton JA; Gordon AJ
Drug Alcohol Depend; 2012 May; 122(3):241-6. PubMed ID: 22115887
[TBL] [Abstract][Full Text] [Related]
4. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration.
Manhapra A; Petrakis I; Rosenheck R
Am J Addict; 2017 Sep; 26(6):572-580. PubMed ID: 28472543
[TBL] [Abstract][Full Text] [Related]
5. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
6. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
7. Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.
Finlay AK; Wong JJ; Ellerbe LS; Rubinsky A; Gupta S; Bowe TR; Schmidt EM; Timko C; Burden JL; Harris AHS
J Stud Alcohol Drugs; 2018 Nov; 79(6):909-917. PubMed ID: 30573022
[TBL] [Abstract][Full Text] [Related]
8. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
9. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
10. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
[TBL] [Abstract][Full Text] [Related]
11. Trends in Opioid Use Disorder Diagnoses and Medication Treatment Among Veterans With Posttraumatic Stress Disorder.
Shiner B; Leonard Westgate C; Bernardy NC; Schnurr PP; Watts BV
J Dual Diagn; 2017; 13(3):201-212. PubMed ID: 28481727
[TBL] [Abstract][Full Text] [Related]
12. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder.
Bello JK; Xu KY; Salas J; Bedrick BS; Grucza RA
J Gen Intern Med; 2024 Jun; 39(8):1342-1348. PubMed ID: 38424347
[TBL] [Abstract][Full Text] [Related]
13. Sex Differences in Opioid Use Disorder Prevalence and Multimorbidity Nationally in the Veterans Health Administration.
Peltier MR; Sofuoglu M; Petrakis IL; Stefanovics E; Rosenheck RA
J Dual Diagn; 2021; 17(2):124-134. PubMed ID: 33982642
[TBL] [Abstract][Full Text] [Related]
14. Use of naltrexone for alcohol use disorders in the Veterans' Health Administration: a national study.
Iheanacho T; Issa M; Marienfeld C; Rosenheck R
Drug Alcohol Depend; 2013 Sep; 132(1-2):122-6. PubMed ID: 23434041
[TBL] [Abstract][Full Text] [Related]
15. Long-acting injectable depot naltrexone use in the Veterans' Health Administration: a national study.
Marienfeld C; Iheanacho T; Issa M; Rosenheck RA
Addict Behav; 2014 Feb; 39(2):434-8. PubMed ID: 23790742
[TBL] [Abstract][Full Text] [Related]
16. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
[TBL] [Abstract][Full Text] [Related]
17. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
Manhapra A; Stefanovics E; Rosenheck R
Subst Abus; 2020; 41(1):110-120. PubMed ID: 31403914
[No Abstract] [Full Text] [Related]
18. Update on pharmacotherapy for treatment of opioid use disorder.
Ayanga D; Shorter D; Kosten TR
Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
20. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
